Dystonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Dec. 15, 2011 - PRLog -- GlobalData estimates that the global dystonia therapeutics market was valued at $606m in 2010 and is expected to grow to $1.02 billion with a projected Compound Annual Growth Rate (CAGR) of 6.7%. Such steady growth in the dystonia therapeutics market is primarily attributed to an increase in the prescription population for botulinum toxin (Botox). An increase in the prevalence of dystonia and disease awareness among patients and physicians will also contribute to this growth.

GlobalData’s analysis suggests that although there is a narrow range of treatments available for treating dystonia, they still meet the current market requirements. Since the dystonia therapeutics market is dominated by biologics, price has also been an area of concern. Biologics, as can be seen from their premium price, have undoubtedly gained control over the dystonia market as the gold-standard therapy for dystonia. With the advent of Dysport and the other forms of botulinum toxins that are anticipated, the expectations from these therapies have increased. The lack of a cure will remain an unmet need in the market in the years to come.

GlobalData’s pipeline analysis revealed that there are six candidates in the various stages of clinical development. First-in-class molecules are mainly distributed in Phase II, Phase II/Phase I, and Phase I. Pipeline products from Phase II and Phase I such as T2000 and ADX48621 appear to be promising. However, it is very unlikely that these molecules will be approved for the treatment of dystonia before
2018. The pipeline molecules differ from each other in terms of mechanism of action, and most have received prior approval for other indications. Most of the research is being carried out by universities, with pharmaceutical and biotechnology companies paying less attention to the development of molecules for dystonia. There are very few commercialization opportunities for the near future owing to a weak pipeline. Newer therapies therefore need to compete with biologics in order to be successful in the dystonia therapeutics market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData, the industry analysis specialist, has released its new report, “Dystonia Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global dystonia market. The report identifies the key trends shaping and driving the global dystonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dystonia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Dyst...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.